Internal medicine, Prostate cancer, Immunology, Oncology and Cancer are his primary areas of study. His Internal medicine study typically links adjacent topics like Surgery. The various areas that James L. Gulley examines in his Prostate cancer study include Docetaxel and Urology.
His studies deal with areas such as Malignancy, Combined Modality Therapy, Metastasis, Disease and Combination therapy as well as Oncology. In the subject of general Cancer, his work in Ipilimumab, Sipuleucel-T and Tumor antigen is often linked to Context, thereby combining diverse domains of study. His Prostate-specific antigen research incorporates themes from Hormonal therapy and Radiation therapy.
The scientist’s investigation covers issues in Internal medicine, Oncology, Prostate cancer, Cancer and Immunology. His research ties Surgery and Internal medicine together. His Oncology research is multidisciplinary, incorporating elements of Enzalutamide, Disease, Chemotherapy and Combination therapy.
He has researched Prostate cancer in several fields, including Prostate and Ipilimumab. The study incorporates disciplines such as Tumor microenvironment and Radiation therapy in addition to Immunotherapy. His research integrates issues of Cancer research and Peripheral blood mononuclear cell in his study of Immune system.
His main research concerns Internal medicine, Oncology, Prostate cancer, Cancer research and Immunotherapy. His Internal medicine study frequently intersects with other fields, such as Gastroenterology. His work carried out in the field of Oncology brings together such families of science as Immune checkpoint, Circulating tumor cell and Phases of clinical research.
Prostate cancer and Prostate are commonly linked in his work. He interconnects Transforming growth factor, PD-L1, Monoclonal antibody and T cell in the investigation of issues within Cancer research. His Immunotherapy research includes themes of Disease and Antigen.
James L. Gulley mostly deals with Internal medicine, Immunotherapy, Oncology, Adverse effect and Clinical trial. His work deals with themes such as Gastroenterology and Antibody, which intersect with Internal medicine. His Immunotherapy study integrates concerns from other disciplines, such as Cancer research, Tolerability and Combination therapy.
His Oncology research includes elements of Immune checkpoint, Enzalutamide, Prostate cancer and Disease. His Prostate cancer research incorporates elements of Concordance and Prostate. His Clinical trial research integrates issues from Neoadjuvant therapy, Metastatic Urothelial Carcinoma, Blockade and Chemotherapy regimen.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Philip W. Kantoff;Thomas J. Schuetz;Brent A. Blumenstein;L. Michael Glode.
Journal of Clinical Oncology (2010)
Androgen Deprivation Therapy for Prostate Cancer
Nima Sharifi;James L. Gulley;William L. Dahut.
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.
Andrea B. Apolo;Jeffrey R. Infante;Ani Balmanoukian;Manish R. Patel.
Journal of Clinical Oncology (2017)
Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer
William L. Dahut;James L. Gulley;Philip M. Arlen;Yinong Liu.
Journal of Clinical Oncology (2004)
Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing Carcinomas
John L. Marshall;James L. Gulley;Philip M. Arlen;Patricia K. Beetham.
Journal of Clinical Oncology (2005)
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer
James L. Gulley;Philip M. Arlen;Anne Bastian;Steven Morin.
Clinical Cancer Research (2005)
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
Benjamin Boyerinas;Caroline Jochems;Massimo Fantini;Christopher R. Heery.
Cancer immunology research (2015)
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Manish R. Patel;John Ellerton;Jeffrey R. Infante;Manish Agrawal.
Lancet Oncology (2018)
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
Philip M Arlen;James L Gulley;Catherine Parker;Lisa Skarupa.
Clinical Cancer Research (2006)
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
James L. Gulley;Philip M. Arlen;Ravi A. Madan;Kwong-Yok Tsang.
Cancer Immunology, Immunotherapy (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: